N4 Pharma appoints Edward Wardle as non-executive director

Published 08/07/2025, 07:38
N4 Pharma appoints Edward Wardle as non-executive director

LONDON - N4 Pharma plc (AIM:N4P), a UK biotech developing the Nuvec gene delivery system, announced Tuesday the appointment of Edward Wardle as a non-executive director, effective immediately.

Wardle joins as a representative of Northern Standard Limited, the company’s largest shareholder. Northern Standard holds 150,000,000 ordinary shares in N4 Pharma, and Wardle personally holds 18,750,000 warrants exercisable at 0.4p per share, expiring April 4, 2030.

The 34-year-old brings experience in strategy, corporate governance and business development to the board. He currently serves as an investment adviser with Tracarta Limited and Northern Standard Limited, focusing on critical industries and technologies, while also working as a Senior Business Development Executive at Ironveld plc.

In May 2025, Wardle joined the board of AIM-listed TheraCryf plc, a clinical stage drug development company specializing in neuropsychiatry and oncology, as a non-executive director.

Nigel Theobald, Chief Executive Officer of N4 Pharma, stated that Wardle’s experience would be "invaluable as N4 Pharma develops its Nuvec platform and continues to build out its data packages to secure licensing opportunities."

Northern Standard Limited is 51% owned by Tracarta Limited, a company in which John Wardle, Edward’s father, has a beneficial interest. Edward Wardle owns 49% of Northern Standard Limited.

The company disclosed that The Dream Corporation Limited, where Wardle serves as a director, is currently undergoing creditors’ voluntary liquidation, with insolvency practitioners appointed in July 2024.

This information is based on a press release statement issued by N4 Pharma.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.